Background The pathophysiology of chronic thromboembolic pulmonary hypertension
(CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher risk …

Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a life‐threatening
complication of a pulmonary embolism (PE) whose incidence and predictors are not …

Background Pulmonary embolism (PE) has a long‐term risk of adverse events, which can be
prevented by extended anticoagulation. We compared clinical characteristics and outcomes …

Background The use of thrombolysis in patients with acute, intermediate-risk pulmonary
embolism (PE) remains controversial. This meta-analysis compared the efficacy and safety …

Background and Aims A large prospective multicentre cohort study with systematic follow-up
recently reported a 2.3% two-year cumulative incidence of chronic thromboembolic …

Background The contemporary natural history of patients with acute pulmonary embolism
(PE) not receiving (or early discontinuing) anticoagulant therapy has not been consistently …

The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary
embolism (PE) is relevant for management decisions but is currently unknown. We …

Introduction Availability of new treatment strategies for patients with acute pulmonary
embolism (PE) have changed clinical practice with potential influence in short-term patients' …

Background: The association between anticoagulation outcomes and prior history of venous
thromboembolism (VTE) in chronic thromboembolic pulmonary hypertension (CTEPH) has …

Aims To systematically assess late outcomes of acute pulmonary embolism (PE) and to
investigate the clinical implications of post-PE impairment (PPEI) fulfilling prospectively …